Drug Repositioning for Refractory Benign Tumors of the Central Nervous System
Drug repositioning (DR) is the process of identifying novel therapeutic potentials for already-approved drugs and discovering new therapies for untreated diseases. DR can play an important role in optimizing the pre-clinical process of developing novel drugs by saving time and cost compared with the...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/16/12997 |
| _version_ | 1797584416789233664 |
|---|---|
| author | Ryota Tamura |
| author_facet | Ryota Tamura |
| author_sort | Ryota Tamura |
| collection | DOAJ |
| description | Drug repositioning (DR) is the process of identifying novel therapeutic potentials for already-approved drugs and discovering new therapies for untreated diseases. DR can play an important role in optimizing the pre-clinical process of developing novel drugs by saving time and cost compared with the process of de novo drug discovery. Although the number of publications related to DR has rapidly increased, most therapeutic approaches were reported for malignant tumors. Surgical resection represents the definitive treatment for benign tumors of the central nervous system (BTCNS). However, treatment options remain limited for surgery-, chemotherapy- and radiation-refractory BTCNS, as well as malignant tumors. Meningioma, pituitary neuroendocrine tumor (PitNET), and schwannoma are the most common BTCNS. The treatment strategy using DR may be applied for refractory BTCNS, such as Grade 2 meningiomas, neurofibromatosis type 2-related schwannomatosis, and PitNETs with cavernous sinus invasion. In the setting of BTCNS, stable disease can provide significant benefit to the patient. DR may provide a longer duration of survival without disease progression for patients with refractory BTCNS. This article reviews the utility of DR for refractory BTCNS. |
| first_indexed | 2024-03-10T23:51:33Z |
| format | Article |
| id | doaj.art-87d51b32de1e4236a605b716ceb957d1 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T23:51:33Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-87d51b32de1e4236a605b716ceb957d12023-11-19T01:33:51ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-08-0124161299710.3390/ijms241612997Drug Repositioning for Refractory Benign Tumors of the Central Nervous SystemRyota Tamura0Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanDrug repositioning (DR) is the process of identifying novel therapeutic potentials for already-approved drugs and discovering new therapies for untreated diseases. DR can play an important role in optimizing the pre-clinical process of developing novel drugs by saving time and cost compared with the process of de novo drug discovery. Although the number of publications related to DR has rapidly increased, most therapeutic approaches were reported for malignant tumors. Surgical resection represents the definitive treatment for benign tumors of the central nervous system (BTCNS). However, treatment options remain limited for surgery-, chemotherapy- and radiation-refractory BTCNS, as well as malignant tumors. Meningioma, pituitary neuroendocrine tumor (PitNET), and schwannoma are the most common BTCNS. The treatment strategy using DR may be applied for refractory BTCNS, such as Grade 2 meningiomas, neurofibromatosis type 2-related schwannomatosis, and PitNETs with cavernous sinus invasion. In the setting of BTCNS, stable disease can provide significant benefit to the patient. DR may provide a longer duration of survival without disease progression for patients with refractory BTCNS. This article reviews the utility of DR for refractory BTCNS.https://www.mdpi.com/1422-0067/24/16/12997drug repositioningdrug repurposingschwannomameningiomapituitary neuroendocrine tumorneurofibromatosis type 2-related schwannomatosis |
| spellingShingle | Ryota Tamura Drug Repositioning for Refractory Benign Tumors of the Central Nervous System International Journal of Molecular Sciences drug repositioning drug repurposing schwannoma meningioma pituitary neuroendocrine tumor neurofibromatosis type 2-related schwannomatosis |
| title | Drug Repositioning for Refractory Benign Tumors of the Central Nervous System |
| title_full | Drug Repositioning for Refractory Benign Tumors of the Central Nervous System |
| title_fullStr | Drug Repositioning for Refractory Benign Tumors of the Central Nervous System |
| title_full_unstemmed | Drug Repositioning for Refractory Benign Tumors of the Central Nervous System |
| title_short | Drug Repositioning for Refractory Benign Tumors of the Central Nervous System |
| title_sort | drug repositioning for refractory benign tumors of the central nervous system |
| topic | drug repositioning drug repurposing schwannoma meningioma pituitary neuroendocrine tumor neurofibromatosis type 2-related schwannomatosis |
| url | https://www.mdpi.com/1422-0067/24/16/12997 |
| work_keys_str_mv | AT ryotatamura drugrepositioningforrefractorybenigntumorsofthecentralnervoussystem |